Linklater's Schmidt on Pfizer-Wyeth's merger review
Linklater's Schmidt on Pfizer-Wyeth's merger review
The approval by U.S. antitrust regulators of Pfizer Inc.'s (NYSE:PFE) acquisition of Wyeth is an outlier of how merger reviews will be conducted under the Obama administration. That's according to Jeffrey Schmidt, a partner with Linklaters and a former director of the Federal show more...
